CD19 and B-cell chronic lymphocytic leukemia: Recently, chimeric antigen receptor (CAR) T cell therapy is being studied that targets B cell-specific antigen in CLL, CD19 (anti-CD19 CART [CTL019]), and observed a promising response in clinical trials for CLL patients (158).